Read our latest news

Press releases

Apr18

- Full Clinical Hold Letter from the FDA Received; Company to Respond in the Coming Weeks -

- Manufacturing-related Partial Clinical Hold on the High Dose of SGT-001 Resolved -

Mar29

Solid Biosciences Inc. (NASDAQ:SLDB) today reported financial results for the full year ended December 31, 2017 and provided a corporate update.

Mar14

Solid Biosciences Inc. (NASDAQ:SLDB) today announced it has received notification from the U.S. Food and Drug Administration ( FDA ) that IGNITE DMD, its Phase I/II clinical trial for SGT-001 microdystrophin gene transfer in Duchenne muscular dystrophy (DMD), has been placed on Clinical Hold.

View our media

Gus

Gus (10) Peterborough, NH

Gals for Cal, women's triathlon 2016

Gals for Cal, women's triathlon 2016

Gals for Cal, women's triathlon 2016

Solid Mission

Solid Organization

Solid Community

Charity Collaboration

Contact information

Kate Niazi-Sai
Senior Director, Corporate Affairs 
media@solidbio.com

More information about Solid?

Please subscribe to receive our latest news